Diabetes More Prevalent in Black Patients With Multiple Myeloma
FRIDAY, Oct. 6, 2023 (HealthDay News) — Diabetes mellitus (DM) is more prevalent among Black patients with multiple myeloma (MM) and is associated with overall survival in MM, especially among White patients, according to a study published online Sep…
Learn MoreIVIg Reduces Infection Rate in Multiple Myeloma Patients Receiving Anti-BCMA Therapy
THURSDAY, Oct. 5, 2023 (HealthDay News) — Many patients with multiple myeloma treated with anti-B cell maturation antigen (BCMA) therapy have infections, and the rate of infections is significantly lower when patients are receiving intravenous immuno…
Learn MoreIVIg Reduces Infection Rate in Multiple Myeloma Patients Receiving Anti-BCMA Therapy
THURSDAY, Oct. 5, 2023 (HealthDay News) — Many patients with multiple myeloma treated with anti-B cell maturation antigen (BCMA) therapy have infections, and the rate of infections is significantly lower when patients are receiving intravenous immuno…
Learn MoreDiabetes Could Speed Progression of Blood Cancer Myeloma
MONDAY, Oct. 2, 2023 (HealthDay News) — Diabetes may accelerate the growth of a blood cancer known as multiple myeloma, affecting overall survival, according to a new study.The research, published Sept. 29 in the journal Blood Advances, also undersco…
Learn MoreBariatric Surgery Linked to Reduced Incidence of Hematologic Cancer
WEDNESDAY, Sept. 27, 2023 (HealthDay News) — Bariatric surgery is associated with reduced incidence of hematological cancer, especially for women, according to a study published online Sept. 13 in The Lancet Healthy Longevity.Kajsa Sjöholm, Ph.D., fr…
Learn MoreFDA Provides Accelerated Approval of Talvey for Multiple Myeloma
TUESDAY, Aug. 15, 2023 (HealthDay News) — The U.S. Food and Drug Administration has approved Talvey (talquetamab-tvgs) for patients with relapsed or refractory multiple myeloma.The accelerated approval is for individuals who have received at least fo…
Learn MoreYounger Patients With Multiple Myeloma Can Achieve Durable Survival
THURSDAY, July 27, 2023 (HealthDay News) — Younger adults with newly diagnosed multiple myeloma who receive an autologous stem cell transplant (auto-HCT) have a median progression-free survival (PFS) of approximately 3.5 years and a median overall su…
Learn MoreMultiple Myeloma Symptoms Are Generally Nonspecific
WEDNESDAY, July 19, 2023 (HealthDay News) — Multiple myeloma (MM) symptoms are generally nonspecific, according to a study published online June 25 in Cancers.Stella Bowcock, M.D., from the King’s College Hospital NHS Trust in the United Kingdom, and…
Learn MoreASCO: Cilta-Cel Beneficial for Lenalidomide-Refractory Multiple Myeloma
THURSDAY, June 8, 2023 (HealthDay News) — For patients with lenalidomide-refractory multiple myeloma, a single cilta-cel infusion results in lower risk of disease progression or death compared with standard care, according to a study published online…
Learn MoreEligibility Criteria May Influence Disparity in Multiple Myeloma Trial Enrollment
MONDAY, May 8, 2023 (HealthDay News) — Eligibility criteria may contribute to racial and ethnic disparities in enrollment in multiple myeloma (MM) clinical trials, according to a study published online May 4 in Blood.Bindu Kanapuru, M.D., from the U….
Learn More